SIRT2 and prostate carcinoma: While it is downregulated in many cancers such as breast cancer, prostate cancer, human gliomas, neck squamous cell carcinoma, colorectal cancer and leukemia [60–65], we report here, according to other studies [66], that SIRT2 is upregulated in melanoma.